Results of Operations and Financial Condition. On August 4, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section…

Class I director — Matthew Pauls: The company appointed Matthew Pauls as a Class I director, expanding the board from seven to eight members.

The filing pertains to an equity plan amendment and does not involve any changes in management or directors.

Results of Operations and Financial Condition. On May 7, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 1…

Class III director — John Doux, M.D.: Dr. John Doux was appointed as a new Class III director.

Results of Operations and Financial Condition. On March 31, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Sectio…

Entry into a Material Definitive Agreement On February 25, 2026, Palvella Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 1,600,000 shares (the “Firm Share…

Results of Operations and Financial Conditions. On February 24, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced that, as of December 31, 2025, the Company had approximately $55.9 million of cash, cash equivalents and marketable securities. The Company has not yet completed its financial close procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company’s consolidated financial statements for the year ended December 31, 2025. Th…

Results of Operations and Financial Condition. On November 11, 2025, Palvella Therapeutics, Inc. (the “ Company ”) expects to issue a press release announcing its financial results for the quarter ended September 30, 2025. In light of the U.S. national holiday on November 11, 2025, the Company is furnishing a copy of such press release as Exhibit 99.1 to this Current Report on Form 8-K and such press release is incorporated herein by reference. The information furnished pursuant to this Item…

Results of Operations and Financial Condition. On August 14, 2025, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Sectio…

Results of Operations and Financial Condition. On May 15, 2025, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section…

Results of Operations and Financial Condition. On March 31, 2025, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Sectio…

The filing is about the approval of a new equity incentive plan, not a management change.

Material Modification to Rights of Security Holders. On December 11, 2024, Pieris Pharmaceuticals, Inc. (“Pieris” or the “Company”) held a special meeting of its stockholders (the “Special Meeting”) at which the Company’s stockholders considered and adopted the proposals outlined in the definitive proxy statement/prospectus statement, dated November 8, 2024 (the “Proxy Statement”), and filed by the Company with the Securities and Exchange Commission (the “SEC”) on November 8, 2024. At the Spe…

Other Events. The closing of the Merger is expected to occur on December 13, 2024, assuming the satisfaction or waiver of all conditions under the Merger Agreement. As previously disclosed, the Company will enter into a Contingent Value Rights Agreement with a rights agent, pursuant to which the Company’s pre-Merger capital stockholders of record on December 12, 2024 will receive one contingent value right for each outstanding share of the Company’s common stock held by such stockholder, or s…

Other Events. As previously announced, on July 23, 2024, Pieris entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Palvella Therapeutics, Inc., a Delaware corporation (“Palvella”), a private, clinical-stage biopharmaceutical company whose vision is to become the leading rare disease biopharmaceutical company focused on developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases, for which there are n…

Unregistered Sales of Equity Securities. The information contained in

Material Modifications to Rights of Security Holders. The information contained in

Entry Into a Material Definitive Agreement. On August 7, 2024, Pieris Pharmaceuticals, Inc. (the “Company”) entered into a Subscription and Investment Representation Agreement (the “Subscription Agreement”) with James Geraghty (the “Purchaser”), Chairman of the Company’s Board of Directors (the “Board”), pursuant to which the Company agreed to issue and sell one (1) share of the Company’s Series F Preferred Stock, par value $0.001 per share (the “Preferred Stock”), to the Purchaser for $1.00…

Unregistered Sales of Equity Securities. The securities to be issued and sold to the PIPE Investors will not be registered under the Securities Act of 1933, as amended (the “ Securities Act ”), and will be issued and sold in reliance on the exemption from registration requirements thereof provided by Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. The disclosure set forth above in

Entry into a Material Definitive Agreement. Merger Agreement On July 23, 2024, Pieris Pharmaceuticals, Inc., a Nevada corporation (“ Pieris ”), Polo Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Pieris (“ Merger Sub ”), and Palvella Therapeutics, Inc., a Delaware corporation (“ Palvella ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set…

Senior Vice President and Chief Development Officer — Shane Olwill, Ph.D.: Dr. Shane Olwill is stepping down from his role as Senior Vice President and Chief Development Officer effective October 31, 2024.

Other Events. As announced on March 27, 2024, the Company implemented a strategy to maximize its ability to capture the potential milestones from its partnered 4-1BB bispecific Mabcalin (antibody-Anticalin fusion) protein immuno-oncology assets, while also maintaining the capability to consider strategic opportunities that it believes may increase stockholder value. The Company continues to remain eligible to receive potential milestone and royalty payments across its remaining partnered 4-1B…

Termination of a Material Definitive Agreement On June 28, 2024, Les Laboratoires Servier and Institut de Recherches Internationales Servier (collectively, "Servier"), provided Pieris Pharmaceuticals, Inc. (the "Company") with a written notice of termination of the License and Collaboration Agreement between Servier, the Company, and Pieris Pharmaceuticals GmbH, dated January 4, 2017, and subsequently amended (the "Collaboration Agreement"). Pursuant to Section 7.1 of the Non-Exclusive Antica…

Material Modification to Rights of Security Holders. The Board of Directors of Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), approved a reverse stock split of the Company’s authorized, issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-80 (the “Reverse Stock Split”). The Company expects that the effective time of the Reverse Stock Split will be at or about 5:00 pm New York time on Monday, April 22, 2024 (th…